|
|
慢性乙型病毒性肝炎合并疾病横断面分析
|
Abstract:
目的：通过对昆明市第三人民医院的慢性乙型病毒型肝炎患者合并疾病情况，了解常见合并疾病，对于相关疾病进行早发现，早干预。方法：统计我院2022年9月~2023年8月期间诊断为“乙型肝炎病毒感染”或“乙型病毒性肝炎”，同时合并其他疾病的患者，根据分类整理分析得出相关结论。结果：本次研究共纳入1200例患者，其中男性806例(67.2%)，女性394例(32.8%)，CHB患者年龄段多集中在31~60岁(72.25%)。一共合并了417种疾病，最常见的合并疾病系统分类前五为消化系统疾病(160.83%)，内分泌、营养、代谢性疾病(107.92%)，血液系统疾病(64.08%)，症状、体征和异常化验结果(62.83%)，循环系统疾病(37.42%)。具体合并疾病前五为白细胞减少(22.33%)，肝纤维化(19.58%)，脾大(17.83%)，高氨血症(17.17%)，甲状腺结节(15.67%)。结论：慢性乙型病毒性肝炎合并疾病种类繁多，其中消化系统疾病和内分泌、代谢性疾病占比过高，应在治疗慢性乙型病毒性肝炎期间严格复查相关指标，警惕合并疾病，降低合并用药导致的毒副作用，进行早期预防，早发现，早干预，提高患者生活质量。
Objective: To understand the common diseases associated with hepatitis B in the Third People’s Hospital of Kunming, and to detect and intervene the related diseases early. Methods: The patients diagnosed with “hepatitis B virus infection” or “hepatitis B virus infection” combined with other diseases in our hospital during September 2022 to August 2023 were counted, and relevant conclusions were drawn according to classification and analysis. Results: A total of 1200 patients were included in this study, including 806 males (67.2%) and 394 females (32.8%). CHB patients were mostly aged 31~60 years old (72.25%). A total of 417 diseases were combined, and the top five most common diseases were digestive system diseases (160.83%), endocrine, nutritional and metabolic diseases (107.92%), blood system diseases (64.08%), symptoms, signs and abnormal laboratory results (62.83%), and circulatory system diseases (37.42%). The top five diseases were leukopenia (22.33%), liver fibrosis (19.58%), splenomegaly (17.83%), hyperammonemia (17.17%) and thyroid nodules (15.67%). Conclusion: There are many kinds of diseases associated with hepatitis B, among which digestive system diseases and endocrine and metabolic diseases account for a high proportion. During the treatment of hepatitis B, we should strictly review the relevant indicators, be alert to the combined diseases, reduce the toxic and side effects caused by combined drugs, carry out early prevention, early detection, early intervention, and improve the quality of life of patients.
| [1] | 赖李群, 徐凯, 吴燕群. 乙型肝炎的流行现状和传播途径及其防控策略[J]. 中国全科医学, 2023, 26(27): 3468. |
| [2] | 中华医学会肝病学分会, 中华医学会感染病学分会. 慢性乙型肝炎防治指南(2022年版) [J]. 中华临床感染病杂志, 2022(6): 401-427. |
| [3] | Tricot, T., Thibaut, H.J., Abbasi, K., Boon, R., Helsen, N., Kumar, M., et al. (2022) Metabolically Improved Stem Cell Derived Hepatocyte-Like Cells Support HBV Life Cycle and Are a Promising Tool for HBV Studies and Antiviral Drug Screenings. Biomedicines, 10, Article No. 268. https://doi.org/10.3390/biomedicines10020268 |
| [4] | Marcellin, P., Wong, D.K., Sievert, W., Buggisch, P., Petersen, J., Flisiak, R., et al. (2019) Ten‐Year Efficacy and Safety of Tenofovir Disoproxil Fumarate Treatment for Chronic Hepatitis B Virus Infection. Liver International, 39, 1868-1875. https://doi.org/10.1111/liv.14155 |
| [5] | WHO (2010) International Statistical Classification of Diseases and Related Health Problems (ICD). |
| [6] | 马蓉霞, 张文杰, 杨晓娟, 等. 不同病因肝硬化患者临床特征及其预后影响因素分析[J]. 现代生物医学进展, 2023, 23(19): 3683-3689. |
| [7] | Wang, L., Xu, X., Zhang, M., Hu, C., Zhang, X., Li, C., et al. (2023) Prevalence of Chronic Kidney Disease in China: Results from the Sixth China Chronic Disease and Risk Factor Surveillance. JAMA Internal Medicine, 183, 298-310. https://doi.org/10.1001/jamainternmed.2022.6817 |
| [8] | Kupin, W.L. (2016) Viral-Associated GN: Hepatitis B and Other Viral Infections. Clinical Journal of the American Society of Nephrology, 12, 1529-1533. https://doi.org/10.2215/cjn.09180816 |
| [9] | Chen, J., Hubbard, A., Bagley, L., Shiau, R., Wong, R.J. and Chitnis, A.S. (2021) Prevalence of Latent Tuberculosis Infection among Persons with Chronic Hepatitis B Virus Infection: A Systematic Review and Meta-Analysis. Digestive Diseases and Sciences, 67, 2646-2654. https://doi.org/10.1007/s10620-021-07056-5 |
| [10] | 杨旭洁, 焦琳, 白浩, 等. 肺结核患者发生乙型肝炎病毒共感染遗传易感性的全基因组关联分析[J]. 华西医学, 2019, 34(8): 885-889. |
| [11] | Bazinet, M., Pantea, V., Placinta, G., Moscalu, I., Cebotarescu, V., Cojuhari, L., et al. (2020) Safety and Efficacy of 48 Weeks REP 2139 or REP 2165, Tenofovir Disoproxil, and Pegylated Interferon Alfa-2a in Patients with Chronic HBV Infection Na？ve to Nucleos(t)ide Therapy. Gastroenterology, 158, 2180-2194. https://doi.org/10.1053/j.gastro.2020.02.058 |
| [12] | Zhang, M., Zhang, Z., Imamura, M., Osawa, M., Teraoka, Y., Piotrowski, J., et al. (2021) Infection Courses, Virological Features and IFN-α Responses of HBV Genotypes in Cell Culture and Animal Models. Journal of Hepatology, 75, 1335-1345. https://doi.org/10.1016/j.jhep.2021.07.030 |
| [13] | Liu, Y., Zheng, Y., Lin, X., Cao, Z., Lu, J., Ma, L., et al. (2023) Analysis of Clinical Characteristics of Thyroid Disorders in Patients with Chronic Hepatitis B Treated with Pegylated-Interferon Alpha. BMC Endocrine Disorders, 23, Article No. 115. https://doi.org/10.1186/s12902-023-01371-w |
| [14] | Ma, Z., Qin, Y., Jia, Y., Xie, Y., Qi, X., Guo, Y., et al. (2022) Thyroid Dysfunction Incidence and Risk Factors in Chinese Chronic Hepatitis B Patients Treated with Pegylated Interferon Alpha: A Long‐Term Follow‐Up Study. Journal of Viral Hepatitis, 29, 412-419. https://doi.org/10.1111/jvh.13667 |
| [15] | Kozielewicz, D., Zale？na, A. and Dybowska, D. (2014) Can Pegylated Interferon α 2a Cause Development of Thyroid Disorders in Patients with Chronic Hepatitis B? Expert Opinion on Drug Safety, 13, 1009-1014. https://doi.org/10.1517/14740338.2014.921156 |
| [16] | Liu, L., Li, P., Mi, Y., Liu, Y., Liu, Y. and Zhang, P. (2019) Thyroid-Stimulating Hormone Is Associated with Nonalcoholic Steatohepatitis in Patients with Chronic Hepatitis B. Medicine, 98, e17945. https://doi.org/10.1097/md.0000000000017945 |
| [17] | Chung, J.W., Choi, H.Y., Ki, M., Jang, E.S. and Jeong, S. (2021) Comorbidities and Prescribed Medications in Korean Patients with Chronic Hepatitis C: A Nationwide, Population-Based Study. Gut and Liver, 15, 295-306. https://doi.org/10.5009/gnl19387 |
